[Edaily Reporter Kim Ji-woo ] HANSAEMK(069640)has decided to cancel its treasury shares, marking a move to expand shareholder returns.
Courtesy of HANSAEMK. HANSAEMK announced on the 2nd that it plans to cancel 667,770 common shares on the 10th. The estimated value of the cancellation is approximately 9.2 billion won.
This cancellation will target treasury shares held by the company and will be carried out by canceling shares acquired within the scope of distributable profits. The company explained that while the number of issued shares will decrease, there will be no reduction in capital.
HANSAEMK plans to reduce the number of shares in circulation and increase per-share value through this treasury stock cancellation. The company explained that this measure is intended to expand its shareholder return policy and strengthen responsible management, in line with the ongoing trend toward enhancing corporate value and protecting shareholder rights.
In addition to the treasury stock cancellation, the company plans to have its major shareholder purchase shares on the open market. Through these measures, the company intends to signal its commitment to enhancing shareholder value to the market and to bolster its efforts to improve corporate value over the medium to long term.
A HANSAEMK official stated, “This share buyback and cancellation is part of our efforts to enhance shareholder value and expand shareholder returns,” adding, “Going forward, we will continue to implement various shareholder-friendly policies based on responsible management to increase corporate value and strengthen trust with our shareholders.”
Meanwhile, HANSAEMK is refining its business portfolio with a focus on core brands and concentrating on improving profitability. Additionally, the company plans to lay the groundwork for future growth by expanding its AI- and data-driven product planning and operational capabilities.
The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…